PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Credit: Getty Images. Balfaxar is a non-activated 4 factor prothrombin complex concentrate containing vitamin K-dependent factors. The Food and Drug Administration (FDA) has approved Balfaxar ® ...
For patients who experience excessive bleeding during cardiac surgery, four-factor prothrombin complex concentrate (4F-PCC), a blood product that contains clotting factors, is significantly more ...
Credit: Octapharma. Balfaxar is a human plasma-derived, purified, virus inactivated and nanofiltered non-activated prothrombin complex concentrate. Balfaxar ® (prothrombin complex concentrate, ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...
About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results